How does Vanflyta (flotetuzumab) work in the body?
Vanflyta’s mechanism of action is based on immune targeting rather than directly killing cells with a small molecule. It is designed to engage the immune system and redirect T cells toward cancer cells by binding both sides of the interaction: the cancer-associated target on tumor cells and a T-cell receptor on immune cells. This brings T cells into close contact with the tumor, helping trigger T-cell–mediated killing of the cancer cells.
What does it bind—tumor cells or T cells?
Vanflyta is structured to bind:
- A marker on tumor cells (so it localizes activity to cancer cells)
- A component on T cells (so it activates and reorients T-cell activity)
By bridging those two cell types, Vanflyta promotes an immune synapse that leads to tumor-cell destruction through T-cell cytotoxic function.
Why is this considered a “targeted immunotherapy” mechanism?
Because its activity depends on the presence of both:
- Cancer cells expressing the relevant tumor marker, and
- Functional T cells in the patient.
That is why the clinical effect depends on immune engagement and the tumor-cell antigen context, not just on blocking a single signaling pathway inside the cancer cell.
What patient effects does the mechanism usually imply?
When a therapy forces T cells to attack tumor cells, it can also increase immune-related side effects. Patients and clinicians often watch for signs of heightened immune activity during treatment (for example, infusion/immune reactions and systemic effects consistent with T-cell activation), since the same mechanism that promotes tumor killing can also drive inflammation.
Sources
No sources were provided in the prompt, and I don’t have Vanflyta’s binding targets or detailed MOA text available here. If you share the prescribing information link or the active ingredient/target details you’re working from, I can restate the exact mechanism precisely.